Structure Therapeutics’ (GPCR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Structure Therapeutics (NASDAQ:GPCR)‘s stock had its “overweight” rating reissued by investment analysts at Cantor Fitzgerald in a report released on Thursday, Benzinga reports. They currently have a $65.00 price target on the stock. Cantor Fitzgerald’s price target would indicate a potential upside of 77.89% from the stock’s current price.

Separately, Lifesci Capital reaffirmed an “outperform” rating on shares of Structure Therapeutics in a research note on Tuesday, February 27th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $85.71.

Structure Therapeutics Trading Down 1.4 %

GPCR traded down $0.53 during trading on Thursday, hitting $36.54. 34,919 shares of the company traded hands, compared to its average volume of 574,664. The company has a market cap of $1.70 billion and a PE ratio of -44.18. The stock’s 50-day simple moving average is $41.02 and its two-hundred day simple moving average is $48.70. Structure Therapeutics has a 1 year low of $21.79 and a 1 year high of $75.02.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Friday, March 8th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. Equities analysts expect that Structure Therapeutics will post -0.98 EPS for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. Wellington Management Group LLP lifted its holdings in shares of Structure Therapeutics by 404.0% in the 4th quarter. Wellington Management Group LLP now owns 4,372,326 shares of the company’s stock worth $178,216,000 after acquiring an additional 3,504,747 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Structure Therapeutics by 835.5% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 1,799,923 shares of the company’s stock worth $90,752,000 after acquiring an additional 1,607,525 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Structure Therapeutics by 133.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,333,333 shares of the company’s stock worth $95,107,000 after acquiring an additional 1,333,333 shares during the last quarter. FMR LLC bought a new stake in shares of Structure Therapeutics in the 1st quarter worth about $29,724,000. Finally, Federated Hermes Inc. lifted its holdings in shares of Structure Therapeutics by 104.2% in the 4th quarter. Federated Hermes Inc. now owns 2,267,206 shares of the company’s stock worth $92,411,000 after acquiring an additional 1,157,006 shares during the last quarter. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.